Cart
sales@molnova.com
Isbogrel
CAS No. 89667-40-3
Isbogrel( —— )
Catalog No. M34289 CAS No. 89667-40-3
Isbogrel (CV4151) is a small molecule thromboxane A2 synthase (TXA2 synthase) inhibitor that can be used to study cardiac arrhythmias, transient ischemic attacks and thrombosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 532 | Get Quote |
|
| 5MG | 787 | Get Quote |
|
| 10MG | 1074 | Get Quote |
|
| 25MG | 1463 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameIsbogrel
-
NoteResearch use only, not for human use.
-
Brief DescriptionIsbogrel (CV4151) is a small molecule thromboxane A2 synthase (TXA2 synthase) inhibitor that can be used to study cardiac arrhythmias, transient ischemic attacks and thrombosis.
-
DescriptionIsbogrel (CV4151) is a small molecule thromboxane A2 synthase (TXA2 synthase) inhibitor that can be used to study cardiac arrhythmias, transient ischemic attacks and thrombosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetProstaglandin Receptor
-
RecptorProstaglandin Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number89667-40-3
-
Formula Weight281.35
-
Molecular FormulaC18H19NO2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(=C\CCCCC(O)=O)(\C1=CC=CC=C1)/C=2C=CC=NC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Pranoprofen
Pranoprofen is a PGE2 inhibitor with IC50 of 7.5 μM.
-
BW 245C
BW 245C is a selective prostaglandin-like DP receptor (DP1) agonist, a prostaglandin analogue with inhibitory effects on the aggregation response of collagen, which can be used to study diseases such as stroke.
-
2-Acetylbenzoic acid
2-Acetylbenzoic acid is more potent than 2-propionyloxybenzoic acid in inhibiting platelet function and platelet prostaglandin (PG) synthesis although the potencies of these agents were comparable in inhibiting prostacyclin (PGI2) synthesis.
